Aurora Cannabis Stock: What Caused the Q3 Revenue Declines?

Aurora Cannabis reported 3 unique causes of revenue decline last quarter that triggered its stock’s decline. All 3 could go away during 2021.

| More on:
analyze data

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s premium investing services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn more

The embattled marijuana producer Aurora Cannabis (TSX:ACB)(NYSE:ACB) is still undergoing a second wave of business transformation, but a key segment is still generating persistent yet serious problems for the firm, thereby weakening its stock price.

The truth is, recreational marijuana sales are still expected to be the major revenue growth driver for Canadian pot companies. When this segment’s sales stutter, it’s a huge concern for Aurora Cannabis stock valuation. Shares traded 7% lower on Friday as investors assessed the marijuana company’s latest quarterly earnings results for its fiscal third quarter  2021 which ended on March 31 of this year.

What happened?

Aurora Cannabis’s net revenue for the March quarter at $55.2 million was down 18% sequentially from December 2020 levels and 25% weaker year over year.

Although medical cannabis revenue increased by 17% annually, adult-use sales declined by 53% from comparable levels last year, and they were 37% lower on a sequential quarterly basis.

As a result, adjusted EBITDA losses worsened sequentially to a $24 million loss for the quarter, and the total Q3 net loss was a painful $164.7 million or $0.85 per diluted share.

The company’s recreational cannabis segment continues to present recurring problems for the firm. Medical cannabis sales remain stable, with medical cannabis derivatives at record highs last quarter, but the adult-use products portfolio has brought so much anguish and suffering for investors.

Among the several moving parts that caused painful revenue declines are three significant factors that Aurora Cannabis stock investors need to watch closely during the remainder of 2021.

Three causes of Aurora Cannabis’s revenue decline last quarter

First, we know that provincial bodies reduced their ordering activity during the period as COVID-19 restrictions negatively impacted sales. There was no pantry loading as there was during the first wave of the coronavirus pandemic in 2020. This phenomenon wasn’t unique to the firm as its peers like Aphria (now Tilray) suffered sales losses too.

However, the company had two unique issues that exacerbated its situation.

The company was going through a transition in its sales functions when Aurora Cannabis decided to shift from an internal sales force to an outsourced marketing model. Management reports that there was a temporary decrease in the number of sales representatives for ACB’s products during the quarter. Has Great North Distributors (the new marketing agent) sorted the issue?  Hopefully, this phenomenon is just but history today.

Most noteworthy, ACB initiated a major product swap initiative recently, and this temporarily reduced orders from provinces as they worked through recent deliveries of new stocks. The company has been upgrading the THC (a psychoactive cannabinoid) content in its product offerings to attract higher demand. Management then reported about $88 million in inventory write-downs for the quarter. Perhaps higher THC offerings will improve future market uptake for the company’s products.

Foolish bottom line

Aurora Cannabis has created a very concerning reputation of disappointing its stock investors, and the latest earnings results were no different. However, it’s also possible that the company is turning a curve this time around given the ongoing restructuring exercise and product portfolio transformations.

All three of the highlighted causes of revenue declines for ACB seem temporary as Canada wins the fight over COVID-19 through vaccinations. Aurora Cannabis stock investors should watch this ailing giant closely. It could pleasantly surprise them during subsequent quarters of the calendar year 2021.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Brian Paradza has no position in any of the stocks mentioned.

More on Cannabis Stocks

edit Cannabis leaves of a plant on a dark background
Cannabis Stocks

Canopy Growth Stock: The Only Cannabis Stock to Consider Long Term

The cannabis stock industry remains an incredibly high risk one, but Canopy Growth (TSX:WEED)(NYSE:CGC) stock provides the best opportunity for…

Read more »

edit Cannabis leaves of a plant on a dark background
Cannabis Stocks

Should You Stay Away From HEXO Stock?

HEXO (TSX:HEXO)(NASDAQ:HEXO) stock is on a downward spiral, and there is little hope it is going to recover soon.

Read more »

edit Cannabis leaves of a plant on a dark background
Cannabis Stocks

Why Did Aurora Cannabis (TSX:ACB) Stock Plunge 75% in 2022?

A prominent cannabis stock has plunged by 75% in 2022, as the company’s losses continue to mount in the face…

Read more »

Pot stocks are a riskier investment
Cannabis Stocks

Fire & Flower: A Small Pot Stock Poised for Strong Growth

Fire & Flower is a cannabis retailer well-positioned for growth thanks to its digital and delivery initiatives.

Read more »

edit Jars of marijuana
Cannabis Stocks

Why Aurora Cannabis (TSX:ACB) Stock Is Sinking This Week

Starting another round of capital raising has hurt investor sentiments, and the Canadian cannabis giant’s performance on the stock market…

Read more »

edit Jars of marijuana
Cannabis Stocks

Why Canopy Growth (TSX:WEED) Stock Plunged 19% Last Week

Canopy Growth Corp. (TSX:WEED)(NASDAQ:CGC) stock has plunged after the release of its final fiscal 2022 results.

Read more »

Cannabis stocks have fallen.
Cannabis Stocks

Why Aurora Cannabis (TSX:ACB) Stock Tanked 45% Last Week

There's no respite for Aurora Cannabis investors!

Read more »

Money growing in soil , Business success concept.
Cannabis Stocks

TFSA Investors: This Undervalued Gem Could Turn $6,000 Into $25,000

Here's why TFSA investors can hold undervalued growth stocks such as Verano in their portfolios right now.

Read more »